How to buy Sigilon Therapeutics stock | $11.67

Sigilon Therapeutics, Inc is a biotechnology business based in the US. Sigilon Therapeutics shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.

Sigilon Therapeutics stock price (NASDAQ: SGTX)

Use our graph to track the performance of SGTX stocks over time.

Sigilon Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$11.67
52-week range	$5.38 - $54.32
50-day moving average	$9.26
200-day moving average	$20.45
Wall St. target price	$42.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Sigilon Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Sigilon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sigilon Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sigilon Therapeutics price performance over time

Historical closes compared with the close of $11.67 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	8.96%
3 months (2021-04-29)	-20.83%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Sigilon Therapeutics financials

Revenue TTM	$12.9 million
Gross profit TTM	$-40,114,000
Return on assets TTM	-25.21%
Return on equity TTM	-85.81%
Profit margin	0%
Book value	$4.10
Market capitalisation	$175.6 million

TTM: trailing 12 months

Shorting Sigilon Therapeutics shares

There are currently 641,029 Sigilon Therapeutics shares held short by investors – that's known as Sigilon Therapeutics's "short interest". This figure is 76.3% up from 363,500 last month.

There are a few different ways that this level of interest in shorting Sigilon Therapeutics shares can be evaluated.

Sigilon Therapeutics's "short interest ratio" (SIR)

Sigilon Therapeutics's "short interest ratio" (SIR) is the quantity of Sigilon Therapeutics shares currently shorted divided by the average quantity of Sigilon Therapeutics shares traded daily (recently around 327055.6122449). Sigilon Therapeutics's SIR currently stands at 1.96. In other words for every 100,000 Sigilon Therapeutics shares traded daily on the market, roughly 1960 shares are currently held short.

To gain some more context, you can compare Sigilon Therapeutics's short interest ratio against those of similar companies.

• Sarepta Therapeutics (SRPT.US): 6.61
• Rubius Therapeutics (RUBY.US): 9.6

However Sigilon Therapeutics's short interest can also be evaluated against the total number of Sigilon Therapeutics shares, or, against the total number of tradable Sigilon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sigilon Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sigilon Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0453% of the tradable shares (for every 100,000 tradable Sigilon Therapeutics shares, roughly 45 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sigilon Therapeutics.

Find out more about how you can short Sigilon Therapeutics stock.

Sigilon Therapeutics share dividends

We're not expecting Sigilon Therapeutics to pay a dividend over the next 12 months.

Sigilon Therapeutics overview

Sigilon Therapeutics, Inc. , a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017.

Frequently asked questions

What percentage of Sigilon Therapeutics is owned by insiders or institutions?
Currently 22.238% of Sigilon Therapeutics shares are held by insiders and 62.788% by institutions. How many people work for Sigilon Therapeutics?
Latest data suggests 99 work at Sigilon Therapeutics. When does the fiscal year end for Sigilon Therapeutics?
Sigilon Therapeutics's fiscal year ends in December. Where is Sigilon Therapeutics based?
Sigilon Therapeutics's address is: 100 Binney Street, Cambridge, MA, United States, 02142